Coherus Oncology (CHRS) Notes Payables (2013 - 2025)

Coherus Oncology (CHRS) posted Notes Payables of $26.2 million for Q1 2025, up 92.57% sequentially from $13.6 million in Q4 2024.

Coherus Oncology (CHRS) Notes Payables (2013 - 2025) Analysis & Trends

Coherus Oncology has reported Notes Payables for 11 years, with the latest figure at $26.2 million in Q1 2025.

Quarterly Notes Payables changed N/A year-over-year to $26.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $26.2 million (changed N/A YoY) and the FY2024 annual result came in at $13.6 million, changed N/A from the prior year.
Notes Payables climbed to $26.2 million in Q1 2025 per CHRS's latest filing, from $13.6 million in the prior quarter.
Over five years, Notes Payables peaked at $81.0 million in Q3 2021 and troughed at $90000.0 in Q2 2023.
A 4-year average of $33.4 million and a median of $13.6 million in 2024 frame the typical range for Notes Payables.
The widest YoY moves for Notes Payables: up 10124.44% in 2024, down 10124.44% in 2024.
Over 4 years, Notes Payables stood at $81.0 million in 2021, then slumped by 99.89% to $90000.0 in 2023, then jumped by 15033.33% to $13.6 million in 2024, then surged by 92.57% to $26.2 million in 2025.
According to Business Quant data, Notes Payables over the past three periods registered $26.2 million, $13.6 million, and $9.2 million for Q1 2025, Q4 2024, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Coherus Oncology	203.82 Mn	98.51 Mn	10.07 Mn

Download Data